CompletedNCT00571922
A Clinical Trial of Acamprosate for Treatment of Methamphetamine Addiction
Medication studyAges 18–99United States
Understand this study
Who was this study for?
Listed age limits: 18 years to 99 years.
- Listed locations
- New YorkSee all locations and recruitment
- Study phase
- Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
Study information
Study start dateJuly 2007
- Recruitment status
- Completed
- Enrollment listed in the registry
- 72
- Sponsor
- NYU Langone Health
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 1, Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
- Locations
- United States
- Age range
- From 18 Years to 99 Years
- Official registry ID
- NCT00571922
- Official title
Show the full official title
A Placebo-controlled, Double Blind, Randomized Trial of Acamprosate for the Treatment of Methamphetamine Dependence
Recruitment & locations
CompletedNew York
Questions about this study
Who is behind this study?
The study sponsor is NYU Langone Health.
Did this study involve medication?
Yes. The study involved medication, including Acamprosate and placebo.
Who was this study for?
Listed age limits: 18 years to 99 years.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit me